TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05083195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Telerehabilitation
Description: Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Brochure
Description: Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
Study: NCT05399498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 25mg capsule
Study: NCT05616364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol intravenous
Study: NCT05423535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)
Description: Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
Study: NCT06014229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
Study: NCT06395181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Diet
Description: A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
Study: NCT06200337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle acupuncture
Description: All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle acupuncture
Description: All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle acupuncture
Description: All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
Study: NCT06096870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at 12.0 microgram/kg by subcutaneous injection (every 28 days)
Study: NCT05423535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)
Description: Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
Study: NCT06334328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based mindful movement therapy
Description: VR-MMT combines VR games, multisensory and cognitive stimulation, hand-eye and full body coordination, creative processes, expressive movement, mindfulness practice, and social connectedness.
Study: NCT06329726

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examinations and clinical scales administration
Description: Psychometric assessment of cognitive and behavioral outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examinations and clinical scales administration
Description: Psychometric assessment of cognitive and behavioral outcomes
Study: NCT05850780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
Study: NCT05742425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With FOLFIRI and Bevacizumab
Description: For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
Study: NCT04559438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotary Neoniti GPS file
Description: Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual stainless steel K-files
Description: Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
Study: NCT05237102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid shunt
Description: The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）
Study: NCT06483802

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ASP2016
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study: NCT06043986

Intervention type: DEVICE
Intervention: novel nurse call system
Description: Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money.
Study: NCT05961800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cutaneous Probe
Description: A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
Study: NCT05237102

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cerebrospinal fluid shunt
Description: The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）
Study: NCT06061822

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-assisted cardiac magnetic resonance imaging
Description: An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
Study: NCT05961800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Tasks
Description: Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
Study: NCT06486363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin combined with clopidogrel
Description: Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin combined with half-dose ticagrelor
Description: Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
Study: NCT05770258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study: NCT06061822

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AI-assisted cardiac magnetic resonance imaging
Description: An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
Study: NCT06145737

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)
Description: One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module.
Study: NCT06513013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block in cesarean section
Description: .an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block in cesarean section
Description: .an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: 25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 250 mg of MgSO4) to keep the total volume the same in both group
Study: NCT05183542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale \< 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
Study: NCT04377932

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AGAR T cells
Description: Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2 DL2: 1x10\^8/m2 DL3: 3x10\^8/m2 DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study: NCT05887700

Intervention type: DEVICE
Intervention: CeraFlex™ Atrial Septal Defect (ASD) Closure System
Description: The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
Study: NCT06229132

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGBTQ-affirmative CBT for transgender individuals
Description: The intervention addresses unique stressors encountered by transgender individuals due to discrimination and lack of adequate and affirming healthcare resources.
Study: NCT04995523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Study: NCT05320055

Intervention type: PROCEDURE
Intervention: robotic repair
Description: robotic assisted retromuscular hernia repair

Intervention type: PROCEDURE
Intervention: robotic repair
Description: robotic assisted retromuscular hernia repair
Study: NCT06368440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive AZD6793 single dose as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive AZD6793 single dose as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive AZD6793 single dose as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive AZD6793 multiple doses daily as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive AZD6793 multiple doses daily as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as oral suspension.
Study: NCT06524063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survivin-loaded dendritic cell injection
Description: The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
Study: NCT05179967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-JAAA Stent Graft System
Description: WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.